摘要
目的观察吉西他滨对晚期肺鳞癌与肺腺癌治疗的疗效差别,为临床上晚期肺癌的化疗的药物筛选提供依据。方法肺鳞癌组31例与肺腺癌组37例分别接受吉西他滨(1 000 mg/m2)加顺铂(75 mg/m2)或卡铂(AUC=5)化疗,每21 d为1周期,每2个周期考评疗效。结果鳞癌组31例和腺癌组37例均能进行临床评价。鳞癌组中部分缓解(partial response,PR)为10例(32.2%),稳定(stable disease,SD)为14例(45.2%),进展(progressive disease,PD)为7例(22.6%),完全缓解(complete response,CR)为24例(77.4%)。中位生存期为12月,1年生存率为54.8%(17/31)。腺癌组中PR为11例(29.7%),SD为18例(48.7%),PD为8例(21.6%),CR为29例(78.4%)。中位生存期为9月,1年生存率为29.7%(11/37)。结论吉西他滨对肺鳞癌与肺腺癌的疾病控制相近,但对鳞癌表现出比腺癌更高的生存时间与生存率。
Objective To evaluate the effects of treatment of advanced squamous carcinoma and adenocarcinoma of lung by Gemcitabine. Methods Thirty-one patients of squamous carcinoma and 37 patients of adenocarcinoma of lung received chemotherapy of Gemcitabine（ 1 000 mg/m^2 ） plus Cisplatin（75 mg/m^2 ） or Carboplatin（AUC = 5 ） every 21 days as a cycle. The therapeutic efficacy was evaluated after 2 cycles of chemotherapy. Results Thirty-one patients of squamous carcinoma and 37 patients of adenocarcinoma of lung were objectively evaluated. In squamous carcinoma patients partial response （PR） was 10 （32.2%）, stable disease （SD） was 14（45.2% ）, progressive disease （PD） was 7（22.6% ）, complete response （CR） was 24 （77. 4%）. Median survival time was 12 months and 1-year survival rate was 54. 8% （17/31）. In adenocarcinoma PR was 11 （29.7%）, SD was 18 （48.7%）, PD was 8 （21.6%）, CR was 29 （78.4%）. Median survival time was 9 months and 1-year survival rate was 29.7% （11/37）. Conclusion The control of squamous carcinoma and adenocarcinoma of lung treated by Gemcitabine was similar, but the survival time and survival rate of squamous carcinoma are higher than those of adenocarcinoma.
出处
《同济大学学报（医学版）》
CAS
2009年第1期77-80,共4页
Journal of Tongji University(Medical Science)
